Barclays PLC Avadel Pharmaceuticals PLC Transaction History

Barclays PLC

  • $377 Billion
  • Q3 2024

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 15, 2024
SELL
$9.64 - $14.59 $231 - $350
-24 Reduced 50.0%
24 $0
Q3 2023

Nov 07, 2023
SELL
$10.3 - $15.99 $507,656 - $788,099
-49,287 Reduced 99.9%
48 $0
Q2 2023

Aug 03, 2023
BUY
$8.48 - $16.48 $418,360 - $813,040
49,335 New
49,335 $813,000
Q4 2021

Feb 14, 2022
SELL
$7.34 - $11.18 $1,130 - $1,721
-154 Closed
0 $0
Q3 2021

Nov 09, 2021
SELL
$6.49 - $9.91 $3,595 - $5,490
-554 Reduced 78.25%
154 $1,000
Q2 2021

Aug 13, 2021
SELL
$6.73 - $9.05 $91,494 - $123,034
-13,595 Reduced 95.05%
708 $4,000
Q1 2021

May 13, 2021
BUY
$6.61 - $10.07 $581 - $886
88 Added 0.62%
14,303 $130,000
Q4 2020

Feb 11, 2021
BUY
$5.03 - $7.95 $1,006 - $1,590
200 Added 1.43%
14,215 $95,000
Q3 2020

Nov 12, 2020
SELL
$5.02 - $8.98 $133,532 - $238,868
-26,600 Reduced 65.49%
14,015 $71,000
Q2 2020

Aug 12, 2020
BUY
$7.25 - $11.75 $192,603 - $312,150
26,566 Added 189.1%
40,615 $328,000
Q1 2020

May 13, 2020
BUY
$4.06 - $10.64 $57,038 - $149,481
14,049 New
14,049 $111,000
Q2 2019

Aug 14, 2019
SELL
$1.09 - $3.19 $7 - $22
-7 Closed
0 $0
Q1 2019

May 15, 2019
SELL
$1.44 - $3.29 $99 - $227
-69 Reduced 90.79%
7 $0
Q4 2018

Feb 14, 2019
SELL
$1.74 - $4.66 $252 - $675
-145 Reduced 65.61%
76 $0
Q3 2018

Nov 14, 2018
SELL
$4.08 - $7.14 $3,264 - $5,712
-800 Reduced 78.35%
221 $1,000
Q2 2018

Aug 14, 2018
SELL
$5.89 - $7.78 $6,773 - $8,947
-1,150 Reduced 52.97%
1,021 $6,000
Q1 2018

May 15, 2018
SELL
$6.76 - $11.7 $36,497 - $63,168
-5,399 Reduced 71.32%
2,171 $15,000
Q4 2017

Feb 14, 2018
BUY
$8.03 - $11.25 $28,145 - $39,431
3,505 Added 86.22%
7,570 $61,000
Q3 2017

Nov 14, 2017
BUY
$8.35 - $10.5 $33,942 - $42,682
4,065
4,065 $43,000

Others Institutions Holding AVDL

# of Institutions
8
Shares Held
1.07M
Call Options Held
0
Put Options Held
0
View Full List

About AVADEL PHARMACEUTICALS PLC

AVDL Quotes by TradingView
  • Ticker AVDL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 60,581,300
  • Market Cap $650M
  • Description
  • Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...
More about AVDL
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email